Two chemotherapy schedules for newly diagnosed low-risk DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares two different shortened treatment schedules of R-CHOP to see which one is safer and works better for people with low-risk diffuse large B-cell lymphoma (DLBCL). It aims to reduce risk from treatment while maintaining strong cancer control after an initial response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed DLBCL that tests positive for CD20.
- You have not had any cancer treatment before, and you’re newly diagnosed.
- After 4 cycles of R-CHOP, your PET scan looks in complete response (Deauville 1–2).
- Your overall risk score is low (IPI 0 or 1), and you’re able to do daily activities normally (ECOG 0–1).
- Your heart pumping function is adequate (left heart ejection fraction above 50%).
- Blood tests and organ tests during screening meet required minimums (or the results are clearly from lymphoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a “mini-CHOP-like” chemotherapy plan for newly diagnosed diffuse large B-cell lymphoma (DLBCL) in people age 70 and older. It may help you learn whether this gentler regimen works well and is safe in older adults who are newly starting treatment.
This trial tests if a new drug combination (R-CMOP) works as well as or better than the usual combination (R-CHOP) for people with a type of lymphoma called DLBCL who haven't had treatment yet.
This trial tests a lower-dose combination of chemotherapy drugs (R-mini-MCOP) for people aged 80 or older who have just been diagnosed with a common type of lymphoma called DLBCL. The goal is to see if this gentler approach is effective and easier to tolerate.
This trial tests a new combination treatment (DZD8586) for people with diffuse large B-cell lymphoma (DLBCL). It looks at how well the drug works and how safe it is for both newly diagnosed patients and those whose cancer returned after initial treatment.
This trial tests whether adding a targeted drug (X) to the standard Pola-R-CHP regimen works better for people with DLBCL whose cancer didn't respond well after the first cycle of chemo. It compares the standard treatment to a combination with an extra drug, aiming to improve outcomes for those who need it most.
This trial tests whether adding personalized, low-dose radiation therapy to standard chemotherapy improves outcomes for newly diagnosed diffuse large B-cell lymphoma (DLBCL). The radiation plan is tailored based on how well your cancer responds to chemotherapy early on.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.